Division of Oncology and Radiotherapy, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Department of Clinical Oncology, School of Medicine University of Zagreb, Croatia.
Acta Clin Croat. 2022 Oct;61(Suppl 3):32-44. doi: 10.20471/acc.2022.61.s3.5.
Optimal sequencing of available therapy lines in patients with advanced prostate cancer often poses quite a challenge. The guidelines are sometimes equivocal and clinical trial data are not always applicable to a particular patient. There is a difference in availability of therapy options throughout the world. In decision making, a patient as a whole should be taken into consideration, not just the stage and biology of the disease, but also patient's age, performance status, comorbidities, previous therapy lines, drug's safety profile and patient's preferences. This review article will show certain therapeutic options in the treatment of advanced hormone-sensitive prostate cancer and castration resistant prostate cancer: non- metastatic and metastatic. An attempt will be made to clarify the optimal sequencing.
在晚期前列腺癌患者中，优化可用治疗线的序贯治疗常常是一个挑战。指南有时并不明确，临床试验数据并不总是适用于特定患者。世界各地的治疗选择的可用性存在差异。在决策中，不仅要考虑疾病的阶段和生物学特性，还要考虑患者的年龄、体能状态、合并症、既往治疗线、药物的安全性特征和患者的偏好，应将患者作为一个整体来考虑。本文将介绍晚期激素敏感型前列腺癌和去势抵抗性前列腺癌（非转移性和转移性）的某些治疗选择，并尝试阐明最佳的序贯治疗方案。
